Several
enzymes are involved in the energy production, becoming a possible target for new anti-
cancer drugs. In this paper, we used biochemical and in silico studies to evaluate the effects of two
guanidine molecules, (Boc)2 -
creatine and
metformin, on
creatine kinase, an
enzyme involved in the regulation of intracellular energy levels. Our results show that both drugs inhibit
creatine kinase activity; however, (Boc)2 -
creatine displays a competitive inhibition, while
metformin acts with a non-competitive mechanism. Moreover, (Boc)2 -
creatine is able to inhibit the activity of
hexokinase with a non-competitive mechanism. Considering that
creatine kinase and
hexokinase are involved in energy metabolism, we evaluated the effects of (Boc)2 -
creatine and
metformin on the
ATP/
AMP ratio and on cellular proliferation in healthy fibroblasts, human
breast cancer cells (MDA-MB-468), a human
neuroblastoma cell line (SH-SY5Y), a human
Hodgkin lymphoma cell line (KMH2). We found that healthy fibroblasts were only partially affected by (Boc)2 -
creatine, while both
ATP/
AMP ratio and viability of the three
cancer cell lines were significantly decreased. By inhibiting both
creatine kinase and
hexokinase, (Boc)2 -
creatine appears as a promising new agent in anticancer treatment. Further research is needed to understand what types of
cancer cells are most suitable to treatment by this new compound. J. Cell. Biochem. 118: 2700-2711, 2017. © 2017 Wiley Periodicals, Inc.